GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Australian Clinical Labs Ltd (ASX:ACL) » Definitions » Asset Impairment Charge

Australian Clinical Labs (ASX:ACL) Asset Impairment Charge : A$0.0 Mil (TTM As of Dec. 2023)


View and export this data going back to 2021. Start your Free Trial

What is Australian Clinical Labs Asset Impairment Charge?

Australian Clinical Labs's Asset Impairment Charge for the six months ended in Dec. 2023 was A$0.0 Mil. Its Asset Impairment Charge for the trailing twelve months (TTM) ended in Dec. 2023 was A$0.0 Mil.


Australian Clinical Labs Asset Impairment Charge Historical Data

The historical data trend for Australian Clinical Labs's Asset Impairment Charge can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Australian Clinical Labs Asset Impairment Charge Chart

Australian Clinical Labs Annual Data
Trend Dec20 Jun21 Jun22 Jun23
Asset Impairment Charge
- - - -

Australian Clinical Labs Semi-Annual Data
Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Asset Impairment Charge Get a 7-Day Free Trial - - - - -

Australian Clinical Labs Asset Impairment Charge Calculation

Asset Impairment Charge is the charge against earnings resulting from the aggregate write down of all assets from their carrying value to their fair value.

Asset Impairment Charge for the trailing twelve months (TTM) ended in Dec. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was A$0.0 Mil.


Australian Clinical Labs Asset Impairment Charge Related Terms

Thank you for viewing the detailed overview of Australian Clinical Labs's Asset Impairment Charge provided by GuruFocus.com. Please click on the following links to see related term pages.


Australian Clinical Labs (ASX:ACL) Business Description

Traded in Other Exchanges
N/A
Address
1868-1892 Dandenong Road, Clayton, VIC, AUS, 3168
Australian Clinical Labs, or ACL, is Australia's third-largest private pathology provider. ACL earns almost its entire group revenue from pathology services in Australia, which are mostly earned via the publicly funded health Medicare system. ACL is well-established in the states of Western Australia, South Australia, Victoria and the Northern Territory.

Australian Clinical Labs (ASX:ACL) Headlines

No Headlines